3D Bioprinting Patent Landscape 2026
3D Bioprinting Patent Landscape in 2026
The 3D bioprinting patent field spans 5,612 patent families and is at a maturity stage, with annual volume having plateaued near its 2022 peak while the multi-year window still shows positive growth. Organovo leads by family count, but the field is moderately fragmented across academic and commercial applicants, with biomaterial science and additive manufacturing process claims forming the dominant technology core.
Organovo leads a moderately fragmented field with a significant academic tier
Organovo holds the top position with 225 patent families, ahead of Wake Forest University Health Sciences (166) and Lung Biotech (106). The top five filers together account for 20% of the hundred largest filers’ combined total, signalling a moderate — not extreme — degree of concentration at the head of the ranking.
A distinct academic tier occupies positions two through ten, including Harvard, the University of California system, CNRS, and Carnegie Mellon, reflecting the foundational research character of the field. Commercial applicants such as Lung Biotech, Sichuan Revotek, and Rokit Healthcare sit alongside these institutions, indicating that industry is beginning to consolidate positions but has not yet displaced academic leadership.
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 1 | Organovo Inc. | 225 | |
| 2 | Wake Forest University Health Sciences Inc. | 166 | |
| 3 | Lung Biotech PBC | 106 | |
| 4 | PRESIDENT & FELLOWS OF HARVARD COLLEGE | 105 | |
| 5 | Sichuan Revotek Co. Ltd. | 97 | |
| 6 | Regents of the University of California | 84 | |
| 7 | French National Centre for Scientific Research (CNRS) | 82 | |
| 8 | Rokit Healthcare Inc. | 76 | |
| 9 | Polbionica Sp. z o.o. | 74 | |
| 10 | University of Missouri | 69 |
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 11 | Advanced Solutions Life Sciences LLC | 67 | |
| 12 | CollPlant Ltd. | 63 | |
| 13 | Carnegie Mellon University | 62 | |
| 14 | Accelerated Biosciences Corp. | 60 | |
| 15 | Université Claude Bernard Lyon 1 | 58 | |
| 16 | The University of Queensland | 54 | |
| 17 | POSTECH (Pohang University of Science and Technology) Academy-Industry Foundation | 54 | |
| 18 | Rice University | 51 | |
| 19 | Inventia Life Science Pty Ltd. | 50 | |
| 20 | Ronawk Inc. | 47 |
Organovo’s lead in family count, combined with a filing trajectory that has eased in recent years, suggests the company is defending an established portfolio rather than aggressively expanding it. Challengers with rising momentum — notably Lung Biotech and Aspect Biosystems — represent the most active competitive pressure points for incumbents to monitor.
Filing counts for 2024–2026 are likely under-represented owing to the standard 18–24 month patent publication lag; rankings and trend reads for that period should be treated as provisional. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Annual volume plateaued after a 2022 peak; biomaterials and process IP dominate the mix
Two charts together show where 3D bioprinting activity has been concentrated in time and in technology space. The filing trend reveals a field that expanded rapidly to 2022 and has since stabilised, while the IPC composition chart exposes a technology mix anchored by biocompatible materials and additive manufacturing process claims.
Annual filing trend
Filings climbed from 484 in 2017 to a peak of 798 in 2022, then eased to 757 in 2023 and 612 in 2024. The 2025 and 2026 bars are substantially under-counted due to publication lag and should not be read as further decline. The 14% recent-window growth confirms the multi-year trajectory is still positive even as annual peaks are behind us.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61L (biocompatible materials and sterilisation) and B33Y (additive manufacturing) are the two largest branches, each with over 3,000 records, closely followed by C12N (microorganisms and cell engineering). B29C (plastics shaping) and C12M (bioreactors) form a secondary cluster. Lower-density branches such as A61F (implants), G01N (material testing), and A61K (medicinal preparations) flag adjacent areas where filing intensity is comparatively sparse.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Biogum and botanical gum hydrogel bioinks for the …
Bioink compositions comprising a biomaterial (mammalian, plant based, synthetically derived, or microbially derived) such as a hydrogel and a microbial-, fungal-, or plant-produced polysaccharide, with or without cells, for use in the 3D bioprinting of human tissues and scaffolds are described. The bioink compositions have excellent printability and… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | System and method for producing clinical models an… | 177 |
| 2 | Self-Assembling Cell Aggregates and Methods of Mak… | 158 |
| 3 | Bioprinted Nanoparticles and Methods of Use | 157 |
| 4 | Three Dimensional Tissue Generation | 130 |
| 5 | Well-defined degradable poly(propylene fumarate) p… | 125 |
| 6 | Additive manufacturing of embedded materials | 124 |
| 7 | Methods of generating functional human tissue | 109 |
| 8 | Self-assembling cell aggregates and methods of mak… | 107 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents.
What the competitive structure means for R&D investment decisions
Four structural observations — maturity stage, concentration tier, collaboration networks, and geographic coverage — each carry distinct implications for where new investment will face competition and where room to manoeuvre remains.
Field is at plateau: established positions, selective white space
Annual filings peaked in 2022 and have since plateaued, placing 3D bioprinting in a maturity stage. New entrants face a dense prior-art landscape in core biomaterial and process IP. The strategic implication is that incremental improvements to mainstream bioink or extrusion technology are harder to protect; durable positions require differentiation into application-specific or bioreactor-integration claims.
Maturity stageModerate concentration: no single entity holds commanding dominance
The top five filers account for 20% of the hundred largest filers’ combined total — enough to signal influence but not lock-in. The gap between Organovo (225 families) and the tenth-ranked applicant (69 families) is substantial, yet the midfield remains populated by active academic and start-up filers. This structure leaves room for targeted portfolio building in under-covered application domains.
Moderate concentrationCNRS anchors the dominant co-filing network; Organovo co-files with industry
CNRS is the most active co-filer in the landscape, collaborating most heavily with Université Claude Bernard Lyon 1 (60 joint families), CPE Lyon (35), and INSA Lyon (31), forming a tightly linked French academic cluster. Organovo co-files with Oregon Health & Science University (25 families) and L’Oréal (9), illustrating a bridge between biomedical and cosmetics applications. ETH Zurich and TU Delft form a smaller cross-border academic pair (9 families).
Academic-led networksUS leads by a wide margin; Europe and PCT routes are active secondary channels
The United States is the primary filing jurisdiction, followed by Europe (EPO) and WIPO (PCT). India and Australia rank fourth and fifth, ahead of Canada and China — an unusual ordering that may reflect specific applicant strategies rather than broad market coverage. Japan and South Korea, despite hosting active bioprinting research communities, show comparatively lower filing volumes, suggesting possible gaps in Asia-Pacific protection strategies.
US-led, global reachGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| French National Centre for Scientific Research (CNRS) | Université Claude Bernard Lyon 1 | 60 |
| French National Centre for Scientific Research (CNRS) | CPE Lyon (Ecole Superieure de Chimie Physique Electronique de Lyon) | 35 |
| French National Centre for Scientific Research (CNRS) | INSA Lyon (Institut National des Sciences Appliquées de Lyon) | 31 |
| Organovo Inc. | Oregon Health & Science University | 25 |
| French National Centre for Scientific Research (CNRS) | Sartorius Stedim FMT SAS | 25 |
| French National Centre for Scientific Research (CNRS) | Université de Technologie de Lyon | 16 |
| French National Centre for Scientific Research (CNRS) | LAB SKIN CREATIONS | 15 |
| Organovo Inc. | L’Oréal | 9 |
| ETH Zurich | Delft University of Technology | 9 |
| French National Centre for Scientific Research (CNRS) | Centrale Nantes | 8 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Organovo anchors cell-biology IP; Aspect Biosystems rises fast on hardware and process claims
The top two players by family count occupy distinct technology lanes. Organovo’s portfolio is concentrated in cell engineering and tissue characterisation, while Aspect Biosystems (Anspex Biological Systems) is rapidly building hardware and additive-manufacturing process IP from a smaller base.
Organovo
Organovo holds 225 patent families — the largest portfolio in the field — concentrated in cell and tissue engineering (C12N5), material analysis and testing (G01N33), and biocompatible scaffold materials (A61L27). Its recent filing momentum has declined 59% versus the prior period, indicating a shift from aggressive portfolio expansion toward defending existing positions. Teams evaluating the cell-tissue engineering space must navigate Organovo’s dense prior art.
families: 225Aspect Biosystems
Aspect Biosystems (listed as Anspex Biological Systems in the evidence) is the fastest-rising established challenger, with recent filings running at 4.1× the prior three-year rate. Its technology focus is on plastics-shaping processes (B29C64) and additive manufacturing apparatus and methods (B33Y30, B33Y10), distinguishing it sharply from the cell-biology emphasis of Organovo and Wake Forest. This hardware-and-process orientation positions it as the leading IP threat in printhead and biomaterial delivery system claims.
families: rising rapidly| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Organovo Inc. | 12 | ▼ -59% |
| Wake Forest University Health Sciences | 12 | ▼ -25% |
| Aspect Biosystems Ltd. | 66 | ▲ 4.1× vs prior 3-yr |
| President & Fellows of Harvard College | 18 | ▲ +20% |
| Lung Biotech PBC | 98 | ▲ new entrant |
| Regents of the University of California | 17 | ▼ -59% |
Under-served adjacent branches in implants, drug formulation, and material testing
Relative to the dominant biomaterial and additive-manufacturing core, several adjacent IPC branches show meaningfully lower filing density. These observations are based on share within the top-IPC ranking and should be evaluated against technical feasibility and freedom-to-operate before treating them as investment targets.
A61F · Implants & prostheses
With 689 records against a dominant core exceeding 3,000 in the top branches, implant and prosthesis-specific claims represent one of the most accessible adjacent areas. 3D bioprinting is directly applicable to patient-specific implant fabrication, yet the filing density here is roughly one-fifth of the biomaterials branch. Applicants with existing regulatory experience in implantable devices and biocompatible scaffold expertise hold a plausible entry path into this space.
Search this in Eureka →G01N · Material analysis & testing
Material analysis and testing (G01N) sits at 474 records — sparse relative to the fabrication and materials chemistry branches. As bioprinted constructs move toward clinical and regulatory use, in-process and post-print characterisation methods become critical. Claims covering printability metrics, mechanical testing protocols, and in vitro functional assays for bioprinted tissues are comparatively thin. Organisations developing quality-control or analytical instrumentation for bioprinting workflows face relatively limited prior-art density here.
Search this in Eureka →How leading applicants differ by technology route emphasis
Strength of each leader across the main technology routes.
| Player | A61L 27 · Sterilising & disinfecting | C12N 5 · Microorganisms & genetic engineering | B33Y 70 · Additive manufacturing (3D printing) | B33Y 10 · Additive manufacturing (3D printing) | B29C 64 · Shaping of plastics |
|---|---|---|---|---|---|
| Aspect Biosystems Ltd. | Strong · 65 | Strong · 47 | Moderate · 33 | Strong · 66 | Strong · 91 |
| Organovo Inc. | Moderate · 71 | Strong · 184 | Absent | Absent | Absent |
| Wake Forest University Health Sciences | Strong · 69 | Strong · 130 | Absent | Absent | Absent |
| Lung Biotech PBC | Strong · 61 | Absent | Strong · 38 | Strong · 46 | Strong · 41 |
| President & Fellows of Harvard College | Strong · 87 | Strong · 52 | Absent | Moderate · 28 | Absent |
Frequently asked questions
The corpus covers 5,612 patent families in scope. The top 100 applicants account for a significant share of that total, with the top five alone representing 20% of the hundred largest filers’ combined count.
Organovo holds the largest portfolio with 225 patent families, focused primarily on cell and tissue engineering and biocompatible scaffold materials. Wake Forest University Health Sciences is second with 166 families.
On a multi-year basis, yes — the recent window shows 14% growth. However, annual filing volume peaked in 2022 at 798 records and has plateaued since. The field is classified as mature rather than rapidly expanding. Apparent further drops in 2024–2026 reflect publication lag, not confirmed decline.
The United States is the primary jurisdiction, followed by Europe (EPO) and WIPO (PCT). India and Australia rank fourth and fifth. China, despite a growing bioprinting industry, ranks seventh, which may reflect applicant-level filing strategies rather than the full scope of Chinese innovation.
Lung Biotech is a new entrant showing 98 recent families. Aspect Biosystems is filing at 4.1× its prior three-year rate. Harvard’s President & Fellows shows a 20% increase. By contrast, Organovo and the University of California system have each declined 59% in recent filings versus their prior periods.
CNRS is the hub of the largest co-filing network, partnering most intensively with Université Claude Bernard Lyon 1 (60 joint families), CPE Lyon (35), and INSA Lyon (31). Organovo co-files with Oregon Health & Science University (25 families) and L’Oréal (9 families), bridging biomedical and cosmetics application domains.
Map your own position in the 3D bioprinting landscape
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.